Related Experiment Videos
Single-agent mitomycin for advanced non-small cell lung cancer
1Mid Kent Oncology Centre, Maidstone General Hospital, Maidstone, UK.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|May 26, 2001
Summary
Mitomycin demonstrated a 20% response rate in advanced non-small cell lung cancer patients. This single-agent chemotherapy offers a potential treatment option, balancing drug activity against toxicity for improved patient outcomes.
Area of Science:
- Oncology
- Medical Oncology
- Pharmacology
Background:
- Advanced non-small cell lung cancer (NSCLC) treatment lacks a consensus chemotherapy regimen.
- Balancing drug efficacy and toxicity is crucial in NSCLC chemotherapy.
- Single-agent chemotherapy is of continued interest for NSCLC management.
Purpose of the Study:
- To evaluate the efficacy of mitomycin as a single-agent chemotherapy in advanced non-small cell lung cancer.
- To determine the response rate and survival outcomes associated with mitomycin treatment.
Main Methods:
- A study was conducted on 20 patients with advanced non-small cell lung cancer.
- Patients received mitomycin as a single-agent chemotherapy.
- Response rates and median survival were assessed.
Main Results:
- Four out of 20 patients showed a response, yielding a response rate of 20% (95% CI 3-37).
- The median survival observed was 26 weeks (95% CI 13-30).
- One patient with bone and liver metastases survived for 27 months post-treatment.
Conclusions:
- Mitomycin shows a 20% response rate in advanced non-small cell lung cancer.
- Single-agent mitomycin offers a potential treatment option with manageable toxicity.
- Further investigation into mitomycin's role in NSCLC treatment is warranted.